Revolution Medicines/$RVMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
- Ticker
- $RVMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 883
- Headquarters
- Redwood City, United States
- Website
- www.revmed.com
RVMD Metrics
BasicAdvanced
$41B
-
-$8.92
1.41
-
Price and volume
Market cap
$41B
Beta
1.41
52-week high
$224.31
52-week low
$56.66
Average daily volume
2M
Financial strength
Current ratio
11.378
Quick ratio
11.122
Long term debt to equity
0.45
Total debt to equity
0.457
Interest coverage (TTM)
-27.42%
Profitability
EBITDA (TTM)
-1,618.188
Management effectiveness
Return on assets (TTM)
-30.12%
Return on equity (TTM)
-79.09%
Valuation
Price to book
15.74
Price to tangible book (TTM)
16.17
Price to free cash flow (TTM)
-30.776
Free cash flow yield (TTM)
-3.25%
Free cash flow per share (TTM)
-6.216
Growth
Earnings per share change (TTM)
97.14%
3-year earnings per share growth (CAGR)
41.44%
What the Analysts think about RVMD
Analyst ratings (Buy, Hold, Sell) for Revolution Medicines stock.
Analyst projections of the future price of Revolution Medicines stock.
Bulls say / Bears say
FDA approval of RASONQUE for previously treated metastatic pancreatic cancer gives RVMD a commercial foothold, backed by Phase 3 results showing median overall survival of 13.2 months versus 6.7 months with chemotherapy. This is a substantial clinical advance in a cancer with limited treatment options. (Revolution Medicines, Reuters)
The European Medicines Agency’s committee has recommended RASONQUE for marketing authorisation, opening a route to expand sales beyond the US if the European Commission grants final approval. (Revolution Medicines)
RVMD ended the second quarter with $3.9 billion in cash and investments, giving it substantial resources to fund commercial preparations and its late-stage trials. The company also said up to $1.5 billion in additional milestone-linked capital could be available. (Revolution Medicines)
RASONQUE has notable tolerability risks: in pancreatic cancer, rash occurred in 86% of patients and stomatitis in 57%, while gastrointestinal perforation and pneumonitis included fatal cases. These side effects could make treatment management and broad uptake more challenging. (Revolution Medicines)
Spending is rising quickly: RVMD reported $2.1–$2.2 billion in expected 2026 operating expenses after raising its forecast, and its April financing included a 12.1 million-share offering alongside convertible notes. The high burn and equity issuance increase pressure to execute and leave investors exposed to further dilution. (Revolution Medicines, SEC)
The lung-cancer opportunity remains unproven in a randomised trial: the 42% response rate came from a 38-patient subgroup in a Phase 1/2 study, while the confirmatory Phase 3 trial is still under way. If those early results do not hold up, an important source of future growth could fall short. (Revolution Medicines)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.
RVMD Financial Performance
Revenues and expenses
RVMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
RVMD News
AllArticlesVideos
Funds containing RVMD
AllUSDEURGBP
Fund name | Fund size | $RVMD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 2.60% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 2.60% |
Vanguard FTSE Global Small-Cap$VSMU | $15M | 0.40% |
Vanguard FTSE Global Small-Cap£VSML | $15M | 0.40% |
Xtrackers MSCI World Health Care$XDWH | $4.1B | 0.36% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.